AP1/Fra1 confers resistance to MAPK cascade inhibition in pancreatic cancer

[1]  D. Ennishi,et al.  Establishment of a reference single-cell RNA sequencing dataset for human pancreatic adenocarcinoma , 2022, iScience.

[2]  R. Braren,et al.  Identification of treatment‐induced vulnerabilities in pancreatic cancer patients using functional model systems , 2022, EMBO molecular medicine.

[3]  Timothy E. Reddy,et al.  Epigenetic basis of oncogenic-Kras-mediated epithelial-cellular proliferation and plasticity. , 2022, Developmental cell.

[4]  N. Kraut,et al.  Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants , 2022, Cancer discovery.

[5]  B. Kuster,et al.  Selective multi-kinase inhibition sensitizes mesenchymal pancreatic cancer to immune checkpoint blockade by remodeling the tumor microenvironment , 2021, Nature Cancer.

[6]  David R. Jones,et al.  Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients , 2021, Cell.

[7]  C. Der,et al.  Targeting the ERK mitogen-activated protein kinase cascade for the treatment of KRAS-mutant pancreatic cancer. , 2022, Advances in cancer research.

[8]  Joshua M. Dempster,et al.  Chronos: a cell population dynamics model of CRISPR experiments that improves inference of gene fitness effects , 2021, Genome Biology.

[9]  A. Trumpp,et al.  TNF-α-producing macrophages determine subtype identity and prognosis via AP1 enhancer reprogramming in pancreatic cancer , 2021, Nature Cancer.

[10]  John G Doench,et al.  SMAD4 represses FOSL1 expression and pancreatic cancer metastatic colonization , 2021, Cell reports.

[11]  G. Schneider,et al.  New insights into pancreatic cancer: notes from a virtual meeting. , 2021, Gastroenterology.

[12]  S. Vicent,et al.  The Transcription Factor SLUG Uncouples Pancreatic Cancer Progression from the RAF–MEK1/2–ERK1/2 Pathway , 2021, Cancer Research.

[13]  D. Calvisi,et al.  FOSL1 promotes cholangiocarcinoma via transcriptional effectors that could be therapeutically targeted. , 2021, Journal of hepatology.

[14]  Wei Xie,et al.  Mutant Kras co-opts a proto-oncogenic enhancer network in inflammation-induced metaplastic progenitor cells to initiate pancreatic cancer , 2020, Nature Cancer.

[15]  S. C. Chafe,et al.  Overcoming Adaptive Resistance to KRAS and MEK Inhibitors by Co-targeting mTORC1/2 Complexes in Pancreatic Cancer , 2020, Cell reports. Medicine.

[16]  R. Rad,et al.  Targeting the ubiquitin‐proteasome system in a pancreatic cancer subtype with hyperactive MYC , 2020, Molecular oncology.

[17]  Laura E. Herring,et al.  Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers , 2020, Cell reports.

[18]  P. Verde,et al.  The nuclear oncoprotein Fra-1: a transcription factor knocking on therapeutic applications’ door , 2020, Oncogene.

[19]  Hans-Peter Lenhof,et al.  GeneTrail 3: advanced high-throughput enrichment analysis , 2020, Nucleic Acids Res..

[20]  A. Ashworth,et al.  HNF4A and GATA6 Loss Reveals Therapeutically Actionable Subtypes in Pancreatic Cancer , 2020, Cell reports.

[21]  Steven J. M. Jones,et al.  Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution , 2020, Nature Genetics.

[22]  Kerstin B. Meyer,et al.  BBKNN: fast batch alignment of single cell transcriptomes , 2019, Bioinform..

[23]  Joshua M. Dempster,et al.  Synthetic Lethal Interaction of SHOC2 Depletion with MEK Inhibition in RAS-Driven Cancers. , 2019, Cell reports.

[24]  Alex Y. Ge,et al.  KRASG12C inhibition produces a driver-limited state revealing collateral dependencies , 2019, Science Signaling.

[25]  Emanuel J. V. Gonçalves,et al.  Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens , 2019, Nature.

[26]  E. Petricoin,et al.  Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer , 2019, Nature Medicine.

[27]  E. Collisson,et al.  Molecular subtypes of pancreatic cancer , 2019, Nature Reviews Gastroenterology & Hepatology.

[28]  J. Yap,et al.  Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers , 2019, Nature Medicine.

[29]  Damian Szklarczyk,et al.  STRING v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets , 2018, Nucleic Acids Res..

[30]  D. Saur,et al.  Oncogenic KRAS and the EGFR loop in pancreatic carcinogenesis—A connection to licensing nodes , 2018, Small GTPases.

[31]  Mazhar Adli,et al.  CRISPR knockout screening identifies combinatorial drug targets in pancreatic cancer and models cellular drug response , 2018, Nature Communications.

[32]  Leland McInnes,et al.  UMAP: Uniform Manifold Approximation and Projection , 2018, J. Open Source Softw..

[33]  Channing J Der,et al.  KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer. , 2018, Cold Spring Harbor perspectives in medicine.

[34]  B. Neel,et al.  SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models. , 2018, Cancer discovery.

[35]  W. Birchmeier,et al.  Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase , 2018, Nature Medicine.

[36]  S. Byers,et al.  Curation of the Pancreatic Ductal Adenocarcinoma Subset of the Cancer Genome Atlas Is Essential for Accurate Conclusions about Survival-Related Molecular Mechanisms , 2018, Clinical Cancer Research.

[37]  James E. Bradner,et al.  The dTAG system for immediate and target-specific protein degradation , 2018, Nature Chemical Biology.

[38]  P. Zarrinkar,et al.  Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor , 2018, Cell.

[39]  Mathias J Friedrich,et al.  Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes , 2018, Nature.

[40]  W. Weichert,et al.  MTOR inhibitor-based combination therapies for pancreatic cancer , 2018, British Journal of Cancer.

[41]  S. Reddy,et al.  FOSL1 Promotes Kras‐induced Lung Cancer through Amphiregulin and Cell Survival Gene Regulation , 2017, American journal of respiratory cell and molecular biology.

[42]  Fabian J Theis,et al.  SCANPY: large-scale single-cell gene expression data analysis , 2018, Genome Biology.

[43]  Elizabeth H. Williams,et al.  GRcalculator: an online tool for calculating and mining dose–response data , 2017, BMC Cancer.

[44]  Beau R. Webber,et al.  Rapid DNA replication origin licensing protects stem cell pluripotency , 2017, bioRxiv.

[45]  S. Vicent,et al.  All for one and FOSL1 for all: FOSL1 at the crossroads of lung and pancreatic cancer driven by mutant KRAS , 2017, Molecular & cellular oncology.

[46]  P. Philip,et al.  Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial , 2017, JAMA oncology.

[47]  Roland Rad,et al.  Tissue-specific tumorigenesis: context matters , 2017, Nature Reviews Cancer.

[48]  P. Khatri,et al.  An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer , 2017, Nature Communications.

[49]  J. Wikel,et al.  Identification and Characterization of New Chemical Entities Targeting Apurinic/Apyrimidinic Endonuclease 1 for the Prevention of Chemotherapy-Induced Peripheral Neuropathy , 2016, The Journal of Pharmacology and Experimental Therapeutics.

[50]  R. Gibbs,et al.  Genomic analyses identify molecular subtypes of pancreatic cancer , 2016, Nature.

[51]  Christoph Ziegenhain,et al.  The impact of amplification on differential expression analyses by RNA-seq , 2016, Scientific Reports.

[52]  R. Rad,et al.  KrasG12D induces EGFR-MYC cross signaling in murine primary pancreatic ductal epithelial cells , 2015, Oncogene.

[53]  J. Wikel,et al.  Identification of new chemical entities targeting APE1 for the prevention of chemotherapy-induced peripheral neuropathy (CIPN) , 2016 .

[54]  Evan Z. Macosko,et al.  Highly Parallel Genome-wide Expression Profiling of Individual Cells Using Nanoliter Droplets , 2015, Cell.

[55]  Fabian J Theis,et al.  A subset of metastatic pancreatic ductal adenocarcinomas depends quantitatively on oncogenic Kras/Mek/Erk-induced hyperactive mTOR signalling , 2015, Gut.

[56]  Mallika Singh,et al.  Modeling Targeted Inhibition of MEK and PI3 Kinase in Human Pancreatic Cancer , 2014, Molecular Cancer Therapeutics.

[57]  M. Loda,et al.  Combined MEK and PI3K Inhibition in a Mouse Model of Pancreatic Cancer , 2014, Clinical Cancer Research.

[58]  Christian Veltkamp,et al.  A next-generation dual-recombinase system for time- and host-specific targeting of pancreatic cancer , 2014, Nature Medicine.

[59]  D. Saur,et al.  MYC and EGR1 synergize to trigger tumor cell death by controlling NOXA and BIM transcription upon treatment with the proteasome inhibitor bortezomib , 2014, Nucleic acids research.

[60]  Joon-Oh Park,et al.  A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas. , 2014, European journal of cancer.

[61]  R. Rad,et al.  Selective requirement of PI3K/PDK1 signaling for Kras oncogene-driven pancreatic cell plasticity and cancer. , 2013, Cancer cell.

[62]  D. Saur,et al.  Efemp1 and p27Kip1 modulate responsiveness of pancreatic cancer cells towards a dual PI3K/mTOR inhibitor in preclinical models , 2013, Oncotarget.

[63]  E. Moding,et al.  Generation of primary tumors with Flp recombinase in FRT-flanked p53 mice , 2011, Disease Models & Mechanisms.

[64]  T. Ciuleanu,et al.  A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy , 2012, Investigational New Drugs.

[65]  P. Yaswen,et al.  A Versatile Viral System for Expression and Depletion of Proteins in Mammalian Cells , 2009, PloS one.

[66]  D. Saur,et al.  E-cadherin regulates metastasis of pancreatic cancer in vivo and is suppressed by a SNAIL/HDAC1/HDAC2 repressor complex. , 2009, Gastroenterology.

[67]  D. Saur,et al.  Pancreas-specific RelA/p65 truncation increases susceptibility of acini to inflammation-associated cell death following cerulein pancreatitis. , 2007, The Journal of clinical investigation.

[68]  P. Verde,et al.  Fra‐1 promotes growth and survival in RAS‐transformed thyroid cells by controlling cyclin A transcription , 2007, The EMBO journal.

[69]  T. Jacks,et al.  Restoration of p53 function leads to tumour regression in vivo , 2007, Nature.

[70]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[71]  E. Wagner,et al.  The Fos‐related antigen Fra‐1 is an activator of bone matrix formation , 2004, The EMBO journal.

[72]  E. Petricoin,et al.  Erratum: Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse (Cancer Cell (4) (437-450)) , 2004 .

[73]  E. Petricoin,et al.  Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. , 2003, Cancer cell.

[74]  Fen Wang,et al.  Cancer cell culture—Methods and protocols , 2003, In Vitro Cellular & Developmental Biology - Animal.

[75]  E. Wagner,et al.  AP-1: a double-edged sword in tumorigenesis , 2003, Nature Reviews Cancer.